Citius Pharmac Dl Stock Current Ratio

47N Stock  EUR 3.29  0.00  0.00%   
CITIUS PHARMAC DL fundamentals help investors to digest information that contributes to CITIUS PHARMAC's financial success or failures. It also enables traders to predict the movement of CITIUS Stock. The fundamental analysis module provides a way to measure CITIUS PHARMAC's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to CITIUS PHARMAC stock.
  
This module does not cover all equities due to inconsistencies in global equity categorizations. Continue to Equity Screeners to view more equity screening tools.

CITIUS PHARMAC DL Company Current Ratio Analysis

CITIUS PHARMAC's Current Ratio is calculated by dividing the Current Assets of a company by its Current Liabilities. It measures whether or not a company has enough cash or liquid assets to pay its current liability over the next fiscal year. The ratio is regarded as a test of liquidity for a company.

Current Ratio

 = 

Current Asset

Current Liabilities

More About Current Ratio | All Equity Analysis

Current CITIUS PHARMAC Current Ratio

    
  32.48 X  
Most of CITIUS PHARMAC's fundamental indicators, such as Current Ratio, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, CITIUS PHARMAC DL is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Typically, short-term creditors will prefer a high current ratio because it reduces their overall risk. However, investors may prefer a lower current ratio since they are more concerned about growing the business using assets of the company. Acceptable current ratios may vary from one sector to another, but the generally accepted benchmark is to have current assets at least as twice as current liabilities (i.e., Current Ration of 2 to 1).
Competition

In accordance with the recently published financial statements, CITIUS PHARMAC DL has a Current Ratio of 32.48 times. This is much higher than that of the Healthcare sector and notably higher than that of the Biotechnology industry. The current ratio for all Germany stocks is notably lower than that of the firm.

CITIUS Current Ratio Peer Comparison

Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses CITIUS PHARMAC's direct or indirect competition against its Current Ratio to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of CITIUS PHARMAC could also be used in its relative valuation, which is a method of valuing CITIUS PHARMAC by comparing valuation metrics of similar companies.
CITIUS PHARMAC is currently under evaluation in current ratio category among its peers.

CITIUS Fundamentals

About CITIUS PHARMAC Fundamental Analysis

The Macroaxis Fundamental Analysis modules help investors analyze CITIUS PHARMAC DL's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of CITIUS PHARMAC using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of CITIUS PHARMAC DL based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.

Currently Active Assets on Macroaxis

Other Information on Investing in CITIUS Stock

CITIUS PHARMAC financial ratios help investors to determine whether CITIUS Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in CITIUS with respect to the benefits of owning CITIUS PHARMAC security.